gip and glp 1 receptor agonist GLP-1 Agonists – Peripheral Brain New Weight-Loss Drugs Are Poised
Description
We need safer alternatives
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ
Methods Event numbers for acute pancreatitis and patient-years of exposure (PYOs) were obtained from representatives of the pharmaceutical companies, or by literature research
Ongoing trials are evaluating their potential benefits in populations with type 2 diabetes mellitus and either CKD or MASLD [101,102]
This could revolutionize obesity treatment - but we need more long-term safety data before it becomes mainstream
